Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

BackgroundBy depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period. The optimal time to vaccinate rituximab-exposed immune-mediated dermatologic disease (IMDD) patients is currently uncle...

Full description

Bibliographic Details
Main Authors:	Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, Ploysyne Rattanakaemakorn, Pichaya O-Charoen, Prapaporn Pisitkun, Thanitta Suangtamai, Chavachol Setthaudom, Sonphet Chirasuthat, Kumutnart Chanprapaph
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Immunology
Subjects:	rituximab anti-CD20 antibody vaccines COVID-19 vaccines immunogenicity immune-mediated dermatologic diseases
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1138765/full

Similar Items

Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial
by: Chutima Seree-aphinan, et al.
Published: (2024-01-01)

Refractory Bullous Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report and Literature Review
by: Ratanapokasatit Y, et al.
Published: (2023-04-01)

Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine
by: Sasipim Chaijaras, MD, et al.
Published: (2022-01-01)

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
by: Kanokrungsee S, et al.
Published: (2021-04-01)

Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
by: Victoria S. Leung, et al.
Published: (2021-08-01)

Linear and Annular Lupus Panniculitis of the Scalp: Case Report with Emphasis on Trichoscopic Findings and Review of the Literature
by: Siriorn Udompanich, et al.
Published: (2019-06-01)

Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia
by: Ben Koszegi, et al.
Published: (2023-03-01)

308-nm Excimer Lamp vs. Combination of 308-nm Excimer Lamp and 10% Liquor Carbonis Detergens in Patients With Scalp Psoriasis: A Randomized, Single-Blinded, Controlled Trial
by: Ploysyne Rattanakaemakorn, et al.
Published: (2021-06-01)

The expansion of activated naive DNA autoreactive B cells and its association with disease activity in systemic lupus erythematosus patients
by: Kittikorn Wangriatisak, et al.
Published: (2021-07-01)

Epidemiological, Clinical, and Trichoscopic Features of Syphilitic Alopecia: A Retrospective Analysis and Systematic Review
by: Cherrin Pomsoong, et al.
Published: (2022-05-01)

Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
by: Fatemeh Saffari, et al.
Published: (2022-01-01)

Rituximab and COVID-19 infection in patients with autoimmune rheumatic diseases – A real-world study from India
by: Aswin M Nair, et al.
Published: (2023-01-01)

Rituximab resistance in ITP and beyond
by: Zhengrui Xiao, et al.
Published: (2023-07-01)

Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis
by: Tanat Yongpisarn, et al.
Published: (2022-12-01)

Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy
by: Maximilian Töllner, et al.
Published: (2022-03-01)

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
by: Remigius Gröning, et al.
Published: (2023-07-01)

Rituximab: historia, farmacología y perspectivas Rituximab: history, pharmacology and perspectives
by: Edgardo E. Espinosa Estrada, et al.
Published: (2010-12-01)

A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort Study
by: Siriorn Sukanjanapong, et al.
Published: (2019-12-01)

Histopathological Evidence of Occipital Involvement in Male Androgenetic Alopecia
by: Saranya Khunkhet, et al.
Published: (2021-11-01)

SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy
by: Liangjian Lu, et al.
Published: (2023-12-01)

Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
by: Per Nived, et al.
Published: (2020-02-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation
by: Martalena Ramli, et al.
Published: (2019-06-01)

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study
by: Hassen Kared, et al.
Published: (2024-02-01)

Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab
by: Victoria Furer, et al.
Published: (2022-06-01)

Rituximab in Autoimmune CNS Disease
by: J Gordon Millichap, et al.
Published: (2014-08-01)

Use of rituximab in systemic lupus erythematosus in children: a review
by: A. N. Arefyeva
Published: (2019-11-01)

Rituximab Leads to Long Remissions in Patients with Chronic Immune Thrombocytopenia
by: Khalid Al-Habsi, et al.
Published: (2015-03-01)

Lupus Nephritis, the therapy and the role of Rituximab in resistant cases
by: Hussein A. Nasir, et al.
Published: (2014-01-01)

Rituximabe na síndrome de Felty refratária Rituximab in the refractory Felty's syndrome
by: Thiago Sotero Fragoso, et al.
Published: (2009-04-01)

Rituximab in Kidney-Limited Microscopic Polyangiitis
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

Bullous Pemphigoid Successfully Treated with Rituximab
by: Nuno Silva, et al.
Published: (2017-03-01)

Current perspective on rituximab in rheumatic diseases
by: Schioppo T, et al.
Published: (2017-10-01)

Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients
by: Cherie Severson
Published: (2015-07-01)

Lupus nephritis, pregnancy and rituximab
by: Enrique Dorado, et al.
Published: (2017-04-01)

Rituximab treatment of pemphigus in women of childbearing age: experience with two patients
by: Eden P. Lake, et al.
Published: (2017-11-01)

Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposure
by: Ana-Luisa Stefanski, et al.
Published: (2022-08-01)